ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting

    EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases

    Lisa Ehlers1, Johan Askling2, Johannes W. J. Bijlsma3, Maria C. Cid4, Maurizio Cutolo5, Bhaskar Dasgupta6, Christian Dejaco7,8, William G Dixon9, Nils Feltelius10,11, Axel Finckh12, Kate Gilbert13, Sarah Mackie14, Alfred Mahr15, Eric L. Matteson16, Lorna Neill17, Carlo Salvarani18,19, Wolfgang A. Schmidt20, Anja Strangfeld21, Ronald van Vollenhoven22 and Frank Buttgereit1, 1Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, 2Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4University of Barcelona, Barcelona, Spain, 5Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 6Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 7Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, 8Rheumatology, Hospital of Bruneck, Bruneck, Italy, 9Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 10Medical Products Agency, Uppsala, Sweden, 11Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, 12University Hospital of Geneva, Geneva, Switzerland, 13Patient Representative from PMRGCAuk, London, United Kingdom, 14NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, 15Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, 16Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 17Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, 18Università di Modena e Reggio Emilia, Modena, Italy, 19Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 20Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 21Epidemiology, German Rheumatism Research Center, Berlin, Germany, 22Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
  • Abstract Number: 2784 • 2018 ACR/ARHP Annual Meeting

    Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis

    Augustin Lecler1, Thomas Sené2, Herve Picard3, Tifenn Leturcq2, Kevin Zuber3, Frederique Charbonneau1, Catherine Vignal-Clermont4 and Gaelle Clavel2, 1Department of Radiology, Fondation Ophtalmologique A. de Rothschild, Paris, France, 2Internal Medecine, Fondation Ophtalmologique A. de Rothschild, Paris, France, 3Clinical Research Unit, Fondation Ophtalmologique A. de Rothschild, Paris, France, 4Ophtalmology, Fondation Ophtalmologique A. de Rothschild, Paris, France

    Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in patient over 50 years of age. It is a medical emergency as it…
  • Abstract Number: 2785 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study

    Ronald van Vollenhoven1, Bevra H Hahn2, George C Tsokos3, Carrie Wagner4, Peter Lipsky5, Benjamin Hsu4, Marc Chevrier4, Robert Gordon4, Kim Hung Lo4, Manon Triebel6, Kaiyin Fei4 and Shawn Rose4, 1Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 2University of California, Los Angeles, CA, 3Beth Israel Hospital, Boston, MA, 4Janssen Research & Development, LLC, Spring House, PA, 5AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, 6Janssen Biologics Europe, Leiden, Netherlands

    Background/Purpose: Both the IL-12 and IL-23 pathways have been linked to SLE pathogenesis. The anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST), which is approved for psoriasis,…
  • Abstract Number: 2786 • 2018 ACR/ARHP Annual Meeting

    Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus

    Vera Golder1, Rangi Kandane-Rathnayake2, Molla Huq3, Worawit Louthrenoo4, Shue-Fen Luo5, Yeong-Jian Wu6, Aisha Lateef7, Sargunan Sockalingam8, Susan Morton9, Sandra V. Navarra10, Leonid Zamora11, Laniyati Hamijoyo12, Yasuhiro Katsumata13, Masayoshi Harigai14, Madelynn Chan15, Sean O'Neill16, Fiona Goldblatt17, Chak Sing Lau18, Zhan-Guo Li19, Alberta Y. Hoi2, Mandana Nikpour20 and Eric Morand21, 1School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 3The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 4Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 5Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 6Chang Gung University, Taoyuan County, Taiwan, 7Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, 8University of Malaya, Kuala Lumpur, Malaysia, 9Monash Health, Melbourne, Australia, 10University of Santo Tomas Hospital, Manila, Philippines, 11Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 12University of Padjadjaran, Bandung, Indonesia, 13Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 14Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, 15Tan Tock Seng Hospital, Singapore, Singapore, 16University of New South Wales, Sydney, Australia, 17Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, 18Medicine, The University of Hong Kong, Hong Kong, Hong Kong, 19Department of Rheumatology and Immunology, People’s Hospital, Peking University Health Science Center,, Beijing, China, 20The University of Melbourne, Melbourne, Australia, Melbourne, Australia, 21Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: The adoption of treat to target approaches for Systemic Lupus Erythematosus (SLE) requires the definition of a target state validated for improved patient outcomes.…
  • Abstract Number: 2787 • 2018 ACR/ARHP Annual Meeting

    −21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)

    Vinod Chandran1, Quan Li2, Rohan Machhar2, Fatima Abji1, Justine Y. Ye1, Rajan Nair3, Philip Stuart3, Katerina Oikonomopoulou2, James T. Elder4, Dafna D Gladman2 and Proton Rahman5, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Michigan, Ann Arbor, MI, 4University of Michigan Medical School, Ann Arbor, MI, 5Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada

    Background/Purpose: The association between human leukocyte antigen (HLA) class I alleles and psoriatic disease indicates a potential role for the innate immune system in disease…
  • Abstract Number: 2788 • 2018 ACR/ARHP Annual Meeting

    The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis

    Michael Walsh1, Peter A. Merkel2 and David Jayne3, 1Nephrology, McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Department of Medicine, University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: It is uncertain whether plasma exchange improves clinical outcomes in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.  Also uncertain is whether, compared to standard therapy with…
  • Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study

    Gulen Hatemi1, Alfred Mahr2, Yoshiaki Ishigatsubo3, Yeong Wook Song4, Melike Melikoglu5, Sue Cheng6, Shannon McCue6, Maria Paris6, Mindy Chen6 and Yusuf Yazici7, 1Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), 5Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 6Celgene Corporation, Summit, NJ, 7New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
  • Abstract Number: 2790 • 2018 ACR/ARHP Annual Meeting

    Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2

    Oskar Schnappauf1, Monique Stoffels2, Ivona Aksentijevich2, Daniel L. Kastner2, Peter C. Grayson3, David Cuthbertson4, Simon Carette5, Sharon A. Chung6, Lindsy J. Forbess7, Nader A. Khalidi8, Curry L. Koening9, Carol Langford10, Carol A. McAlear11, Paul A. Monach12, Larry W. Moreland13, Christian Pagnoux14, Philip Seo15, Jason Springer16, Antoine G. Sreih17, Kenneth J. Warrington18, Steven R. Ytterberg18 and Peter A. Merkel19, 1NHGRI, National Institutes of Health, Bethesda, MD, 2Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, 4Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 6Russell/Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, 7Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 8Rheumatology, McMaster University, Hamilton, ON, Canada, 9Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, 10Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 11Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 12Section of Rheumatology, Boston University School of Medicine, Boston, MA, 13Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 14Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 15Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 16Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, 17Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 18Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 19Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is the first described type of monogenic vasculitis. Patients usually present in childhood, but age of onset, disease…
  • Abstract Number: 2791 • 2018 ACR/ARHP Annual Meeting

    Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression

    Alejandro Gomez, Sarah Kongpachith, Nithya Lingampalli, Cecilia Cisar and William H. Robinson, Department of Medicine, Stanford University, Stanford, CA

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are present in two-thirds of patients with rheumatoid arthritis (RA), and target proteins that have been post-translationally modified by the…
  • Abstract Number: 2792 • 2018 ACR/ARHP Annual Meeting

    The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus

    Laura van Dam1, Zgjim Osmani1, Tineke Kraaij1, Sylvia W.A. Kamerling1, Jaap A. Bakker2, Hans U. Scherer3, Ton Rabelink1, Reinhard Voll4, David A. Isenberg5, Cees van Kooten1 and Y.K. Onno Teng1, 1Nephrology, Leiden University Medical Center, Leiden, Netherlands, 2Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 5University College London, London, United Kingdom

    Background/Purpose: Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease characterized by immune-complexes (ICx) which cause inflammation and damage. Effective targeting of autoantibody secreting…
  • Abstract Number: 2793 • 2018 ACR/ARHP Annual Meeting

    Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis

    Natalia Sherina1, Natalie Sippl1, Lena Israelsson1, Erwan Le Maitre2, Nastya Kharlamova1, Monika Hansson3, Kaja Eriksson4, Tulay Yucel-Lindberg4, Khaled Amara1 and Karin Lundberg1, 1Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Solna,, Karolinska Institutet, Stockholm, Sweden, 3Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPA) is a hallmark of rheumatoid arthritis (RA). ACPAs specifically recognize citrullinated epitopes, a result of a post-translational…
  • Abstract Number: 2794 • 2018 ACR/ARHP Annual Meeting

    Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life

    Mandar Bawadekar1 and Miriam A. Shelef1,2, 1Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, 2William S. Middleton Memorial Veterans Hospital, Madison, WI

    Background/Purpose: Antibodies are a cornerstone of immunity and pathologic in autoimmunity. Immunoglobulin G (IgG) can undergo multiple different post-translation modifications, some of which can alter…
  • Abstract Number: 2795 • 2018 ACR/ARHP Annual Meeting

    IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus

    Huixian Hong1, Qi Wu2, PingAr Yang2, Bao Luo3, Jun Li4, Hao Li5, Daniel Cua6, Hui-Chen Hsu2 and John D. Mountz7, 1University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 3DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 5Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Discovery Research, Merck Research Laboratory, Palo Alto, CA, 7University of Alabama at Birmingham, Devision of Clinical Immunology and Rheumatology; University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: IL-23 is currently a target for several forms of autoimmune diseases, yet its role in promoting pathogenic autoantibody development is less clear. IL-23 was…
  • Abstract Number: 2796 • 2018 ACR/ARHP Annual Meeting

    Sex-Based Differences Control ABC Function in Swef-Deficient Mice

    Michela Manni1, Danny Flores-Castro2, Chao Ye2, Edd Ricker1, Sanjay Gupta3, Yurii Chinenov4, Tania Pannellini2 and Alessandra B. Pernis5, 1Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, 4Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, 5David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

    Background/Purpose: Age-associated B cells (ABCs) are a novel B cell subset, which expands with age in non-autoimmune mice but accumulates prematurely in autoimmune-prone strains. ABCs…
  • Abstract Number: 2797 • 2018 ACR/ARHP Annual Meeting

    Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1

    Sabina Sandigursky1 and Adam Mor2, 1Medicine, NYU School of Medicine, New York, NY, 2Rheumatology and Pathology, NYU School of Medicine, New York, NY

    Background/Purpose: T cells play a major role in the pathogenesis of Rheumatoid Arthritis (RA). These cells are regulated by signals provided via the T cell…
  • « Previous Page
  • 1
  • …
  • 1188
  • 1189
  • 1190
  • 1191
  • 1192
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology